Announcements Trials
Browse Landscape

Phase

Phase NA 39Phase 3 7Phase 2 6Phase 1 3Phase 2/3 1Phase 1/2 1

Status

Completed 4Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 7Thoracic 5Plasma cell 4Endocrine 2CNS 2Other hematologic neoplasm 1NET 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 505Urinary Bladder Neoplasms 139Carcinoma, Renal Cell 117Neoplasms 67Kidney Neoplasms 53Non-Muscle Invasive Bladder Neoplasms 43Neoplasm Metastasis 38Carcinoma, Transitional Cell 38Breast Neoplasms 30Testicular Neoplasms 28Recurrence 20Wilms Tumor 18Parkinson Disease 4, Autosomal Dominant Lewy Body 14Pain 13Ovarian Neoplasms 13Urologic Neoplasms 12Testicular Germ Cell Tumor 12Teratoma 12Seminoma 12Multiple Myeloma 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Carcinoma 11Urogenital Neoplasms 10Neuroblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10

Interventions

Positron-Emission Tomography 2Injections 2technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1lortalamine 1Mitomycin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 3 × Disease × Genitourinary × Clear all
NCT07615101 2026-06-01

Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

Norroy Bioscience Co., LTD

Phase 3 Not yet recruiting
365 enrolled
Genitourinary

Disease, Prostatic Neoplasms

NCT04186845 2025-09-22

Spotlight

Blue Earth Diagnostics

Phase 3 Completed
391 enrolled 30 charts
Genitourinary

Disease, Prostatic Neoplasms

NCT04186819 2025-02-26

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Blue Earth Diagnostics

Phase 3 Completed
356 enrolled 28 charts
Genitourinary

Disease, Prostatic Neoplasms

NCT03739684 2021-06-14

CONDOR

Progenics Pharmaceuticals, Inc.

Phase 3 Completed
208 enrolled 10 charts
Genitourinary

Disease, Prostatic Neoplasms

NCT03335059 2020-04-15

RITE-USA

Medical Enterprises Ltd.

Phase 3 Terminated
5 enrolled
Genitourinary

Urinary Bladder Neoplasms, Disease

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed
531 enrolled
Genitourinary

Disease, Prostatic Neoplasms

NCT00851292 2011-06-22

BIOPRES

Amphia Hospital

Phase 3 Unknown
800 enrolled
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡